Brief: Clarity Pharmaceuticals Gets US FDA Fast Track Designation
19/02/2025 01:36
Feb 19 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* GETS US FDA FAST TRACK DESIGNATION FOR TREATMENT OF
METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial